Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH

Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH

Empagliflozin, an established treatment for type 2 diabetes (T2DM), has shown beneficial effects on liver steatosis and fibrosis in animals and in humans with T2DM, non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH). However, little is known about the effects of empagliflozin on li...

Full description

Bibliographic Details
Main Authors: Nikolaos Perakakis, Pavlina Chrysafi, Michael Feigh, Sanne Skovgard Veidal, Christos S. Mantzoros
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:International Journal of Molecular Sciences
Subjects:
NAFLD
steatosis
SGLT2
lipidomics
liver
NASH
Online Access:https://www.mdpi.com/1422-0067/22/12/6332

Similar Items

Similar Items